T-DM1 Offers Similar PFS, More Tolerable in Advanced HER2-Positive Breast Cancer

The antibody-drug conjugate trastuzumab emtansine (T-DM1) showed non-inferior—but not superior—efficacy to trastuzumab plus a taxane in women with advanced HER2-positive breast cancer, according to a phase III trial. T-DM1 alone and in combination with pertuzumab showed similar results.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.